HCPCS Code J9070: Cyclophosphamide 100 mg billing guide

Key Takeaways

HCPCS Code J9070 describes cyclophosphamide, 100 mg per billed unit, used for Medicare Part B chemotherapy drug billing.

CMS deactivated J9070 effective March 31, 2024, and replaced it with codes J9071–J9075; confirm the current code against the live CMS HCPCS file before billing.

Medicare Part B reimburses cyclophosphamide at ASP+6% under the buy-and-bill model; bill one unit per 100 mg administered.

Practice management software like Pabau helps oncology billing teams track claims, submit them, and reconcile payments in one workflow.

HCPCS Code J9070 identifies cyclophosphamide, 100 mg per billed unit, administered under the Medicare Part B buy-and-bill model for physician-supervised chemotherapy infusion. CMS deactivated J9070 effective March 31, 2024, and replaced it with codes J9071–J9075, which price cyclophosphamide per milligram instead of per 100 mg unit.

The most common error on legacy J9070 claims was billing the full dose as one unit instead of dividing by 100. A 500 mg dose meant 5 units, not 1, and getting it wrong left the practice absorbing roughly 80% of the drug cost. This guide covers the code’s history, the current J9071–J9075 billing mechanics, ASP reimbursement, NDC crosswalk requirements, documentation rules, and a denial-prevention checklist.

HCPCS Code J9070: Definition and quick-reference details

HCPCS Code J9070 was a Level II code maintained by the Centers for Medicare and Medicaid Services (CMS) identifying cyclophosphamide injection at a unit descriptor of 100 mg. CMS deactivated the code effective March 31, 2024, replacing it with codes J9071–J9075. Each billed unit equaled 100 mg of cyclophosphamide administered, and practices billed it under the Medicare Part B buy-and-bill model for physician-supervised infusion in outpatient settings.

Oncology coders, revenue cycle staff, and practice management software teams still rely on J-code reference data to correctly map drug administrations to claim lines, whichever code currently applies.

J9070 code description and drug details

Cyclophosphamide is an alkylating chemotherapy agent used across a broad range of oncology and autoimmune indications. It works by cross-linking DNA strands, preventing cancer cell replication. Clinically, it appears in treatment protocols for non-Hodgkin lymphoma, chronic lymphocytic leukemia, breast cancer, multiple myeloma, and nephrotic syndrome.

Oncology practices administering cyclophosphamide by IV infusion often rely on dedicated IV therapy EMR software to standardize dosing, lot number, and administration records across every infusion drug, not just J9070.

The 100 mg unit descriptor matters for billing. A physician administering 500 mg of cyclophosphamide bills five units of J9070 on the claim line. A 200 mg dose bills as two units. Billing the total dose as one unit is a common error that results in significant underpayment. Prescription management software that keeps organized, accurate prescription and dosing records gives staff a clear reference to double-check the unit count before a claim goes out.

J9070 code status: Deletion history and replacement codes

CMS deactivated HCPCS Code J9070 effective March 31, 2024, replacing it with codes J9071–J9075. The new codes price cyclophosphamide per milligram rather than per 100 mg unit, which changes the unit-calculation formula for any practice still billing from an outdated code table.

Status update: J9070 was deactivated effective March 31, 2024, and replaced by codes J9071–J9075. Some third-party coding databases still list J9070 as active, which creates conflicting information for practices checking their code tables. Confirm current status against the official CMS HCPCS page before submitting any claim.

• Download the current-year HCPCS Level II code file from CMS.gov
• Confirm J9070’s Termination Date (March 31, 2024) alongside the effective date for J9071–J9075
• Verify which of J9071–J9075 applies to the dose administered, since each new code covers a different per-mg range
• Update your billing system’s code table to J9071–J9075 if it still references J9070
• Contact your Medicare Administrative Contractor (MAC) if the correct replacement code is unclear

How to bill J9070: Step-by-step cyclophosphamide billing guidelines

Cyclophosphamide is billed under the Medicare Part B buy-and-bill model. The practice purchases the drug, administers it under physician supervision, and then submits a claim for reimbursement. This is distinct from specialty pharmacy carve-out arrangements, which do not apply to the standard Part B J-code pathway for cyclophosphamide. Practices using Pabau’s claims management software can track claim status, submit claims, and reconcile payments in one workflow, supporting audit readiness.

1. Verify physician supervision: Cyclophosphamide administration under Medicare Part B requires physician supervision at the appropriate level. Direct supervision in an outpatient infusion setting is the standard. Document the supervising physician’s presence or immediate availability.
2. Calculate units accurately: Divide the total administered dose in milligrams by 100. A 500 mg dose = 5 units of J9070. Round down; do not round up to the next unit.
3. Select the correct place of service (POS): POS 11 (office) or POS 22 (outpatient hospital) are most common for infusion. POS affects both coverage rules and reimbursement rates.
4. Attach the NDC: CMS requires National Drug Code reporting on Part B drug claims. Include the 11-digit NDC in the correct loop/segment of the claim (Loop 2410, LIN/CTP segments on 837P electronic claims).
5. Link the diagnosis code: At least one ICD-10-CM code supporting medical necessity for cyclophosphamide must appear on the claim. Use the most specific code available for the patient’s confirmed diagnosis.
6. Submit the administration code: Bill a separate CPT code for the infusion administration (e.g., 96413 for initial chemotherapy infusion, 96415 for each additional hour). J9070 is the drug code only; administration is billed separately.

Medicare reimbursement and ASP pricing for J9070

Medicare Part B reimburses physician-administered drugs at Average Sales Price (ASP) plus 6%, as established under Section 1847A of the Social Security Act. ASP is calculated by CMS from manufacturer sales data and updated quarterly. Each 100 mg unit of J9070 was reimbursed at ASP per 100 mg, multiplied by 1.06, and the same formula now applies per mg under codes J9071–J9075.

Never use a specific dollar figure from a third-party source. Check the current quarter’s CMS Physician Fee Schedule and ASP Drug Pricing file instead, since rates change every January, April, July, and October.

The 6% add-on is intended to cover drug acquisition, handling, and storage costs. Practices participating in the 340B Drug Pricing Program receive a lower acquisition cost but are still reimbursed at ASP+6% by Medicare, with certain exceptions introduced by CMS policy. Consult the HRSA 340B program guidance for current rules. Tracking the spread between acquisition cost and ASP reimbursement is a core revenue cycle metric for oncology practices, and it feeds directly into broader private practice billing efficiency.

NDC crosswalk for cyclophosphamide

A National Drug Code (NDC) crosswalk maps the specific product NDC from the vial label to the HCPCS code used on the claim. CMS requires NDC reporting on Part B drug claims to support Medicaid drug rebate calculations. Failure to include the NDC is a common denial trigger. For Medicare electronic claims (837P), report the NDC in Loop 2410.

NDC reporting rules for Medicaid vary by state. Confirm your state Medicaid agency’s billing companion guide for exact format requirements. Practices with EHR integration for drug billing can keep the NDC on file in the patient’s record and reference it consistently across claims, reducing manual transcription errors.

Documentation requirements for J9070 claims

Every J9070 claim must be supported by a complete medical record that establishes medical necessity. Medicare contractors audit oncology drug claims at elevated rates, and missing documentation is a primary driver of overpayment demands. Practices that standardize their medical office compliance documentation around a pre-claim checklist recover more on first submission and reduce audit exposure.

• Physician order: Written or electronic order specifying drug, dose, route, frequency, and cycle number
• Medical necessity documentation: Confirmed diagnosis with ICD-10-CM code; pathology report or relevant diagnostic test results supporting the cancer diagnosis
• Drug administration record: Start and stop times, actual dose administered, lot number, NDC, and administering staff
• Physician supervision: Documentation of the supervising physician’s presence or immediate availability during infusion
• Prior authorization (if applicable): PA number attached to the claim if required by the payer; PA requirements vary by plan and are not universal under Medicare Fee-for-Service
• HIPAA-compliant record storage: Clinical notes must meet your HIPAA compliance checklist requirements for retention, access controls, and breach notification procedures

The same standards show up in other infusion- and injection-based specialties. Practices running a regenerative medicine EMR track lot numbers and administration times for injectable therapies with the same rigor Medicare expects for oncology drug claims.

ICD-10 codes commonly used with J9070

Medicare coverage for cyclophosphamide is governed by Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors. Always confirm which ICD-10-CM codes are covered under the applicable LCD for your MAC jurisdiction. The table below lists commonly supported diagnoses, though it isn’t a guarantee of coverage. Ensuring patient data security in oncology billing workflows means diagnosis data flows securely from the clinical record to the claim without manual re-entry errors.

Simplify oncology billing workflows with Pabau

Track claims, submit them, and reconcile payments in one place. Pabau's claims management tools help oncology and infusion practices reduce denials and speed up reimbursement.

Book a demo

Related HCPCS J-codes for cyclophosphamide and chemotherapy

Cyclophosphamide has been represented by multiple HCPCS codes over time, covering different formulations and dosing descriptors. Practices that administer other alkylating agents or combination chemotherapy regimens should verify the current active code for each drug in the CMS HCPCS annual update. The AAPC HCPCS code lookup provides a searchable database for J-code verification, and HCPCS Code J1050 is a useful example of another Part B drug code with its own unit and NDC rules.

Common billing errors and denial prevention for J9070

The table below maps the five most common denial drivers to their root cause and fix. Systematic medical practice revenue cycle planning should include a denial tracking log by HCPCS code, so patterns become visible before they compound.

The same wrong-unit and mismatched-place-of-service errors show up in other code families too — CPT Code 00550 and HCPCS Code L0457 follow the same denial logic in anesthesia and orthotics billing.

Conclusion

Unit calculation errors cost oncology billing teams far more than the deleted-code issue does. One claim submitted at 1 unit instead of 5 for a 500 mg dose is an 80% underpayment on the drug line alone, and that adds up fast across a busy infusion schedule.

Pabau’s claims management tools track claim status, support claim submission, and help reconcile payments, so billing teams can catch unit and coding errors before a claim reaches the payer instead of after a denial. To see how Pabau handles oncology and infusion billing workflows, explore how paperless clinical documentation reduces claim errors, or book a demo with the team.

Continue your research

Managing oncology billing compliance? HIPAA compliance software outlines the technical and administrative safeguards required for handling protected health information in clinical billing workflows.

Looking for a structured billing workflow? Practice management software features covers the core tools that support accurate claim submission, from scheduling through payment reconciliation.

Running multiple practice locations? Multi-location management shows how Pabau consolidates billing, scheduling, and compliance documentation across every practice location.

Frequently Asked Questions